Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Maria Goncharova Italy

New.Fa.Dem. searches the new partners worldwide for the distribution of its own products.
New.Fa.Dem, a manufacturing company based in Italy and is authorized by Italian Agency of Drugs.
Conducts activities like R&D, Manufacturing, Distribution of ethical drugs, medical devices and cosmetics with own brand or private labeling.
Manufacturing of Creams, Gels, liquid, powder and suppositories.
Three important certifications:
• ISO 9001: 2015 for compliance with international quality management standards;
• ISO 13485: 2016 for congruence with the legislation relating to the quality of medical devices;
• GMP COMPLIANCE for the possession of authorizations and licenses for the production of pharmaceutical products.
Possibility of manufacturing medical devices and cosmetics of the same form in the facility in the near future.
Successfully present in Europe, Middle East and North Africa.
ISO Certifications for compliance of international standards of Quality Management and rules on the quality of Medical Devices.
Website:
www.newfadem.it
Company Size (Fulltime employees)
51-200
Year of foundation
1971
Partnering Objectives
Please specify your partnering goal
Looking forward for entering into emerging markets either through Distribution agreements or Private Labeling agreements.
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
Lidocaine + Nifedipine|rectal cream|anal fissueres and haemorrhoids|Worldwide
Assets Information 2
Diclofenac|oral drops|pain relief|Worldwide
Biotech/Pharma Asset Stage
New.Fa.Dem. Srl
BD Director 
Functionality
Business Development

Mrs. Loren Gordon United States

It is a University
Website:
uh.edu
Company Size (Fulltime employees)
1-10
Partnering Objectives
Please specify your partnering goal
I am a part of an organization of medical students
Headquartner in China
No
Biotech/Pharma Category
University of Houston
student 
Functionality
Business Development

Mr John Gregg United States

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.
Website:
www.balinbac.com
Year of foundation
2014
Partnering Objectives
Headquartner in China
No
Assets Information 1
BalinBac has a lead clinical stage drug (phase 2/3) repurposed candidate, BB-708, with validated COVID-19 suppressing antiviral activity utilizing multiple recognized mechanisms of action. This SARS-CoV-2 activity has been demonstrated in a number of labs at a drugable micromolar level in human lung cell NHBE and Calu-3 cell line viral neutralization assays. BB-708 is a drug product in a unique inhaled drug delivery system that will stop viral replication of SARS-CoV-2. BalinBac’s multiple MOA anti-coronavirus drugs and inhaled delivery system provides a platform for repurposed therapeutics that will now have 20-year composition of matter patents as NCEs through BalinBac’s proprietary medicinal chemistry. This platform will be extended to other therapeutic areas after addressing the huge unmet need of the COVID-19 pandemic. We are seeking research collaboration and option agreements with big pharma and generic companies and are raising super-angel money to finance some small contributing studies relating to the formulation and for some general operating administrative expenses. We will be delivering the drugs to outpatients via electronic cigarettes in free base form and after this program enters the clinic will be developing a new device for hospital inpatient administration. We would be happy to talk to you about collaboration agreements and early investment.
Biotech/Pharma Asset Stage
Mr John Gregg
BALINBAC THERAPEUTICS, INC.
CEO 
Functionality
Management

Ms. Millie Gu China

Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Website:
https://en.kintor.com.cn/
Company Size (Fulltime employees)
201-500
Year of foundation
11
Partnering Objectives
Please specify your partnering goal
none
Headquartner in China
Yes
Kintor Pharma
PR 

Miao Gu China

Biopharm
Website:
www.genorbio.com
Partnering Objectives
Headquartner in China
Yes
GENOR
AD 

Hayden Gu China

Manufacturing company
Website:
www.avancpharma.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Avancpharma
BD 

Jerax Guo China

generic pharmaceutical listed company
Website:
www.rdpharma.cn
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
珠海润都
BD 

Dr. Morgan Guo Canada

University of Calgary based accelerator
Website:
innovatecalgary.com
Company Size (Fulltime employees)
11-50
Year of foundation
2019
Partnering Objectives
Please specify your partnering goal
looking for partners who are interested in investing/assessing discovery stage technologies, and potentially can partner with our accelerator as CSO
Headquartner in China
No
Assets Information 1
||neuropathic pain|US, UK, CA, DE, FR
Biotech/Pharma Asset Stage
Innovate Calgary
IPM 
Functionality
Business Development

Dr. Yaacov Guy Israel

Project assessment, auditing, project management, regulatory affairs, quality, and IP management services
Website:
www.yztherapeutic.com
Company Size (Fulltime employees)
1-10
Year of foundation
2019
Partnering Objectives
Please specify your partnering goal
desire to expand client base
Headquartner in China
No
Biotech/Pharma Category
YZtherapeutic Performance
CEO 
Functionality
Research and Development

Henry Han United States

EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. For more information regarding EpicentRx, go to: http://www.epicentrx.com.

Website:
https://www.epicentrx.com
Partnering Objectives
Biotech/Pharma Category
Biotech/Pharma Asset Stage
EpicentRx
BD Head 
Functionality
Business Development